Panacea Biotec has important business relationships with various research institutes, academic institutions and commercial corporations:

 
The Institute for Translational Vaccinology (Intravacc), The Netherlands

Panacea Biotec is one of the two companies shortlisted by WHO globally for developing the sabin based injectable polio vaccine (sIPV) and has entered into an agreement with Intravacc (former RIVM) for in-licensing of proprietary know-how for production of sIPV vaccine and related quality control testing for commercialization in India and other international markets.

JSC Binnopharm Inc., Russia (Binnopharm):

Panacea Biotec has entered into a multi-phase supply and technology transfer agreement with Binnopharm for supply of Company's fnished product, viz. Hib Conjugate Vaccine for commercialization in Russian Federation.

National Institute of Immunology, India:

Panacea Biotec has an exclusive ten-year license agreement with National Institute of Immunology, India for in-licensing of technology of Japanese encephalitis vaccine.

 
Dr. Reddy's Laboratories Limited:

Panacea Biotec has a License and Supply Agreement with Dr. Reddy's for its patented product, Nimesulide Transdermal Gel, for marketing, distribution and sale in Russian Federation.

 
PT Bio Farma, Indonesia.

Panacea Biotec has an agreement with PT BioFarma, to manufacture & market the measles vaccine and plans to supply the vaccine to UNICEF, PAHO and CIS, African, LATAM and Asian Countries in furtherance to Global Measles Reduction Strategy of WHO and UNICEF.

 
Kremers Urban Inc. (UCB Group):

Panacea Biotec has entered into a long term contract with Kremers Urban for the distribution of Tacrolimus capsules in US market.